[1] 范建高,重视非酒精性脂肪性肝病的规范化诊疗和推广.中国医学前沿杂志(电子版),2012,4(7):1-3. [2] 徐京杭,多烯磷脂酰胆碱在肝病临床应用的专家共识.中华实验和临床感染病杂志(电子版),2017,11(4):313-319. [3] Djordjevic DB,Zdravkovic M,Nagorni A,et al.A critical approach of guideline therapeutic recommendationsfor NAFLD.Curr Vasc Pharmacol,2017,20(6):1130-1136. [4] World Gastroenterology Organisation.World Gastroenterology Organisation Global Guidelines:Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol,2014,48(6):467-473. [5] 陈九如,肝脏疾病影像学诊断与鉴别诊断(Ⅲ)肝脏病变的影像学诊断与鉴别诊断. 国际医学放射学杂志,2010,33(3):253-265. [6] Shouhed D,Steggerda J,Burch M,et al.The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol,2017,11(9):797-811. [7] Younossi ZM,Loomba R,Anstee QM,et al.Diagnostic modalities for non-alcoholic fatty liver disease(NAFLD),non-alcoholic steatohepatitis (NASH) and associated fibrosis.Hepatology,2017,29(12):106-112. [8] Rana H,Yadav SS,Reddy HD,et al.Comparative effect of insulin sensitizers and statin on metabolic profile and ultrasonographical score in non alcoholic fatty liver disease. J Clin Diagn Res,2016,10(8):19-23. [9] Balasubramanian P,Boopathy V,Govindasamy E,et al.Assessment of portal venous and hepatic artery haemodynamic variation in non-alcoholic fatty liver disease(NAFLD) patients.J Clin Diagn Res,2016,10(8):7-10. [10] Shigefuku R,Takahashi H,Nakano H,et al.Correlations of hepatic hemodynamics,liver function,and fibrosis markers in nonalcoholic fatty liver disease:comparison with chronic hepatitis related to hepatitis C virus. Int J Mol Sci,2016,17(9):224-230. [11] 廖文秋,刘小叶,张琍. 多烯磷脂酰胆碱联合水飞蓟宾治疗非酒精性脂肪肝疗效观察. 实用肝脏病杂志,2014,17(2):196-197. [12] Kim MS,Kim B,Park H,et al.Long-term fermented soybean paste improves metabolic parameters associated with non-alcoholic fatty liver disease and insulin resistance in high-fat diet-induced obese mice.Biochem Biophys Res Commun,2018,495(2):1744-1751. [13] Ferrandino G,Kaspari RR,Spadaro O,et al.Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms.Proc Natl Acad Sci U S A,2017,114(43):172-180. [14] Woods CP,Hazlehurst JM,Tomlinson JW.Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol,2015,154(5):94-103. [15] Pisonero VS,González GJ,Sánchez CS,et al.Flavonoids and related compounds in non-alcoholic fatty liver disease therapy.Curr Med Chem,2015;22(25):2991-3012. [16] Fedelesova M,Kupcova V,Luha J,et al.Paraoxonase activity in sera of patients with non-alcoholic fatty liver disease. Bratisl Lek Listy,2017,118(12):719-720. [17] Banaszczak M,Stachowska E.NAFLD pathogenesis in the light of recent research. Postepy Biochem,2017,63(3):190-197. [18] Ragucci E,Nguyen D,Lamerson M,et al.Effects of mifepristone on nonalcoholic fatty liver disease in a patient with a cortisol-secreting adrenal adenoma.Case Rep Endocrinol,2017,39(12):616-622. |